Lumos Pharma
Lumos Pharma is a clinical stage, biopharmaceutical company developing therapeutics for rare diseases with a focus on pediatric growth hormone deficiency (PGHD). The company is dedicated to transforming lives with a rare focus, advancing therapies through clinical trials, and collaborating with partners to maximize scientific contributions and patient impact.
Industries
Nr. of Employees
small (1-50)
Lumos Pharma
Austin, Texas, United States, North America
Patents
Products
LUM-201
Investigational oral growth hormone secretagogue formulated as an oral tablet and being developed as a potential therapeutic for pediatric growth hormone deficiency.
OraGrowtH clinical trial program
Clinical trial program evaluating an oral growth hormone secretagogue in pediatric growth hormone deficiency, encompassing multicenter Phase 2 efficacy and PK/PD studies.
LUM-201
Investigational oral growth hormone secretagogue formulated as an oral tablet and being developed as a potential therapeutic for pediatric growth hormone deficiency.
OraGrowtH clinical trial program
Clinical trial program evaluating an oral growth hormone secretagogue in pediatric growth hormone deficiency, encompassing multicenter Phase 2 efficacy and PK/PD studies.
Services
In-licensing, exclusive license agreements and strategic alliances to develop and commercialize therapeutic candidates.
Design and management of clinical programs including multicenter Phase 2 studies and PK/PD trials in pediatric populations.
Management of drug substance/product development, process development, technology transfer and clinical supply chain for oral and parenteral products.
In-licensing, exclusive license agreements and strategic alliances to develop and commercialize therapeutic candidates.
Design and management of clinical programs including multicenter Phase 2 studies and PK/PD trials in pediatric populations.
Management of drug substance/product development, process development, technology transfer and clinical supply chain for oral and parenteral products.
Expertise Areas
- Clinical trial management (multicenter, pediatric)
- Pediatric endocrinology therapeutic development
- CMC and clinical supply chain management
- Regulatory strategy and agency interactions
Key Technologies
- Oral small-molecule tablet formulation
- Nanoparticle drug formulations
- Pharmacokinetics and pharmacodynamics (PK/PD) assessment
- Predictive enrichment / biomarker selection
News & Updates
Lumos Pharma announced that topline data from Phase 2 OraGrowtH210 and OraGrowtH212 trials of LUM-201 in PGHD met all primary and secondary endpoints.
Lumos Pharma announced that topline data from Phase 2 OraGrowtH210 and OraGrowtH212 trials of LUM-201 in PGHD met all primary and secondary endpoints.